Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: A retrospective analysis

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 11, 2010, Pages 1729-1735

  Oechsle, Karin ^a   Lange Brock, Victoria ^a   Kruell, Andreas ^a   Bokemeyer, Carsten ^a   De Wit, Maike ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Vivantes Klinikum   (Germany)

Author keywords

Intrathecal chemotherapy; Leptomeningeal metastases; Meningeosis carcinomatosa; Radiotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MENINGEAL METASTASIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SOLID TUMOR; SURVIVAL TIME; TREATMENT RESPONSE; HEMATOLOGIC NEOPLASMS; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM METASTASIS; NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77957584695     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0831-x     Document Type: Article

References (21)

1. K Altundag ML Bondy NQ Mirza SW Kau K Broglio GN Hortobagyi E Rivera 2007 Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis Cancer 110 2640 2647 1:CAS:528:DC%2BD1cXitVOitA%3D%3D 10.1002/cncr.23088 17960791 (Pubitemid 350250332)
2. F Bokstein T Siegal A Lossos 1998 Leptomeningeal metastases from solid tumors, a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy Cancer 82 1756 1763 1:STN:280: DyaK1c3jsFygsA%3D%3D 10.1002/(SICI)1097-0142(19980501)82:9<1764::AID- CNCR24>3.0.CO;2-1 9576299 (Pubitemid 28208928)
3. W Boogerd MJ van den Bent PJ Koehler JJ Heimans JJ van der Sande NK Aaronson AAM Hart J Benraadt CJ Vecht 2004 The relevance of intraventricular chemotherapy for leptomeningeal metastases in breast cancer: a randomised study Eur J Cancer 40 2726 2733 1:CAS:528:DC%2BD2cXhtVahurvE 10.1016/j.ejca.2004.08. 012 15571954 (Pubitemid 39574724)
4. MC Chamberlain 2005 Meningitis neoplastica J Clin Oncol 23 3605 3613 10.1200/JCO.2005.01.131 15908671
5. MC Chamberlain PR Kormanik 1997 Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy J Neuro Oncol 35 55 64 1:STN:280:DyaK2svhtFClsQ%3D%3D 10.1023/A:1005803918194 (Pubitemid 27361846)
6. LM De Angeles D Boutros 2005 Leptomeningeal metastases Cancer Invest 23 145 154
7. K Fizazi B Asselain A Vincent-Salomon M Jouve V Dieras T Palangie P Beuzeboc T Dorval P Pouillart 1996 Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen Cancer 77 1315 1323 1:STN:280:DyaK287pslChug%3D%3D 10.1002/(SICI)1097-0142(19960401)77:7<1315:: AID-CNCR14>3.0.CO;2-4 8608509 (Pubitemid 26102330)
8. L Gaspar C Scott M Rotmann S Asbell T Phillips T Wasserman WG Mc Kenna R Byhardt 1997 Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials Int J Radiat Oncol Biol Phys 37 745 751 1:STN:280:DyaK2s3nsFSmsA%3D%3D 9128946
9. MJ Glantz B Cole L Recht W Akerley P Mills S Saris F Hochberg P Calabresi MJ Egorin 1998 High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16 1561 1567 1:CAS:528:DyaK1cXis1Ghtr0%3D 9552066
10. MJ Glantz S LaFollette KA Jaeckle W Shapiro L Swinnen JR Rozental S Phuphanich LR Rogers JC Gutheil T Batchelor D Lyter MC Chamberlain BL Maria C Schiffer R Bashir D Thomas W Cowens SB Howell 1999 Randomized trial of a slow-release versus a standard formulation of cytarabin for the intrathecal treatment of lymphomatous meningitis J Clin Oncol 17 3110 3116 1:CAS:528:DyaK1MXmslGmtL8%3D 10506606
11. B Gleissner M Chamberlain 2007 Treatment of CNS dissemination in systemic lymphoma J Neurooncol 84 107 117 1:STN:280:DC%2BD2szpslChsQ%3D%3D 10.1007/s11060-007-9353-z 17332946 (Pubitemid 47103452)
12. SA Grossman DM Finkelstein JC Ruckdeschel DL Trump T Moynihan Ettinger DS for the Eastern Cooperative Oncology Group 1993 Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis J Clin Oncol 11 561 569 1:STN:280:DyaK3s7oslKqsA%3D%3D 8445432
13. U Herrlinger H Förschler W Küker R Meyermann M Bamberg J Dichgans M Weller 2004 Leptomeningeal metastasis: survival, prognostic factors in 155 patients J Neurol Sci 223 167 178 10.1016/j.jns.2004.05.008 15337619 (Pubitemid 39164359)
14. EL Kaplan P Meier 1958 Non-parametric estimations from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
15. DY Kim KW Lee T Yun SR Park JY Jung DW Kim TY Kim DS Heo YJ Bang NK Kim 2003 Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone Jpn J Clin Oncol 33 608 612 10.1093/jjco/hyg118 14769837 (Pubitemid 43102813)
16. AB Lassman LE Abrey GG Shah KS Panageas M Begemann MG Malkin JJ Raizer 2006 Systemic high-dose intravenous methotrexate for central nervous system metastases J Neurooncol 78 255 260 1:CAS:528:DC%2BD28Xpt1ylt7s%3D 10.1007/s11060-005-9044-6 16344918 (Pubitemid 44018818)
17. G Pentheroudakis N Pavlides 2005 Management of leptomeningeal malignancy Expert Opin Pharmacother 6 1115 1125 1:CAS:528:DC%2BD2MXltFeksbo%3D 10.1517/14656566.6.7.1115 15957966 (Pubitemid 40959475)
18. JJ Raizer WJ Hwu KS Panageas A Wilton DE Baldwin E Bailey C von Althann LA Lamb G Alvarado MH Bilsky PH Gutin 2008 Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features Neuro Oncol 10 199 207 10.1215/15228517-2007-058 18287337
19. H Rudnicka A Niwińska M Murawska 2007 Breast cancer leptomeningeal metastasis-the role of multimodality treatment J Neuro Oncol 84 57 62 10.1007/s11060-007-9340-4 (Pubitemid 47103444)
20. T Siegal A Lossos MR Pfeffer 1994 Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined modality treatment Neurology 44 1463 1469 1:STN:280:DyaK2czjs1Shsg%3D%3D 8058150
21. S Taillibert H Jerzy 2006 Treatment of central nervos system metastases: parenchymal, epidural, and leptomeningeal Curr Opin Oncol 18 637 643 10.1097/01.cco.0000245323.19411.d7 16988587 (Pubitemid 44427640)